CRISPR-Cas9

[Stem Cell Reports] Phospholamban (PLN) deletion in human induced pluripotent stem cell-cardiomyocytes had enhanced contractility at day 30, but proceeded to a cardiac failure phenotype at day 60, with decreased contractility, mitochondrial damage, increased reactive oxygen species production, cellular energy metabolism imbalance, and poor Ca2+ handling.

[Advanced Science] Investigators developed in vitro methods using a kidney decellularized ECM hydrogel to culture human pluripotent stem cell-derived kidney organoids, which had extensive vascular network and their own endothelial cells.

[Journal of Biomedical Science] 4’,5,7-trihydroxyisoflavone probe was a new chemical probe inhibitor of signal transducer and activator of transcription 1 (STAT1) that reduced stemness and angiogenesis in colorectal cancer.

[Molecular Cancer] The authors evaluate several of the ongoing and future directions of combining next-generation CRISPR-Cas9 gene editing with synthetic biology to optimize CAR T-cell therapy for future clinical trials toward the establishment of a new cancer treatment paradigm.

[Molecular Therapy-Methods & Clinical Development] Scientists demonstrated a liver-specific inhibition of lactate dehydrogenase (LDH) that resulted in a drastic reduction of LDH levels in the liver of primary hyperoxaluria 1 (PH1) and PH3 mice after a single dose delivery of AAV8 vectors expressing CRISPR/Cas9 system, resulting in a reduced urine oxalate levels and kidney damage without signs of toxicity.

[Cell] Scientists identified a family of Enterococcus pore-forming toxins in E. faecalis, E. faecium, and E. hirae strains isolated across the globe.